Navigation Links
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Date:9/19/2007

Results presented at the 43rd European Association for the Study of

Diabetes Annual Meeting

AMSTERDAM, The Netherlands, Sept. 19 /PRNewswire/ -- Results presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS(R) (pioglitazone HCl) to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes. ACTOS is an oral antidiabetic agent for type 2 diabetes belonging to the thiazolidinedione (TZD) class of drugs.

Study Design and Results (PS130 / Abstract #1257)

This retrospective analysis of case records from a large managed care database of patients with diabetes showed that therapeutic regimens that included ACTOS were associated with reductions in the risk for stroke or myocardial infarction (MI) compared to non-thiazolidinedione therapies. The adjusted relative risk of stroke for the ACTOS group was 20 percent lower than that for the group not receiving ACTOS. Likewise, the risk of sustaining a heart attack over the study period was 38 percent lower in the patients receiving ACTOS than in those taking an antidiabetes drug regimen that did not include ACTOS.

"In this study, ACTOS was associated with reduced risk of heart attack and stroke," said Robert Spanheimer, M.D., Takeda Pharmaceuticals North America, Inc., senior medical director of diabetes and metabolism. "These outcomes - in a real world setting - are consistent with findings of no increase in total macrovascular events or death from PROactive, a prospective, randomized, controlled outcomes study."

Case records from January 2003 through June 2006 from a large managed care database of diabetes patients who were at least 45 years of age:

-- had not had a stroke or MI for the last six months and who were taking

either ACTOS (11,433 patients) with or without any other antidiabetes

treatment (excluding rosiglitazone, another member
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... status of the KB001-A development program, including an update ... KB001-A Collaboration Update KaloBios announced ... to regain all rights to KaloBios, KB001-A program. Under ... in 2010 has been terminated. Under that collaboration agreement, ...
(Date:7/28/2014)...  Serco Inc., a provider of professional, technology, ... awarded a re-compete contract to support the Navy ... Medical Systems.  Serco will provide deployable medical systems ... healthcare to meet warfighter and humanitarian requirements in ... five year contract has a one-year base period ...
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... In response to a report recently issued by the ... rising death toll from prescription painkiller overdose, Reckitt Benckiser ... to learn more about the disease of addiction, available ... www.TurnToHelp.com . The new CDC ...
... International, Inc. (NYSE: VRX ) (TSX: VRX) ... to the role of Executive Vice President and Chief ... Valeant, which is expected to be December 1, 2011. ... he was the chief operating officer for the Investment ...
Cached Medicine Technology:New Report Puts Spotlight on Epidemic of Painkiller Abuse and Need for Patient Education and Resources 2Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 2Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 3
(Date:7/28/2014)... gluttons. We have long known that they monopolize large ... some tumor cells are also characterized by a series ... in an ordered set. Researchers are calling this behavior ... EPFL, Etienne Meylan,s research team was able to demonstrate ... mesenchymal behavior result from the same mechanism, at ...
(Date:7/28/2014)... July 29, 2014 The ... Situ Hybridization, Digital pathology & Workflow, Special ... Prostate Cancer, Non Small Cell Lung Cancer ... (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research ... Americas, Europe, BRIC, Japan & RoW) - ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A lush green ... playtime during the summer. However, the summer heat, lack of ... to become brown, weak and unhealthy. The Grounds Guys recommends ... Grow, Mow a lawn once a week and set the ... normal. This protects the grass roots from heat and allows ...
(Date:7/28/2014)... UHY LLP, a member of the ... UHY International Business – Issue 29. This bi-annual publication ... most current business challenges and key issues faced by ... the following topics:, , Key industry ... over the next five years? Where are growth opportunities ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2
... Keynote Afternoon Session on Legal, Regulatory and,Policy Issues, ... healthcare in the United States?, That,s a ... national conference,Personalized Medicine: Promises and Challenges, sponsored by ... and the Food and Drug Law,Institute (FDLI), June ...
... launching a communications revolution, cell phones are talking up ... use of telecommunications technology to provide medical diagnosis and ... thousands of miles apart. Researchers in the United States ... system that uses ordinary cell phone cameras to collect ...
... joins The Libby Ross Foundation to ... unveil celebrity-designed yoga bags, NEW YORK, May 5 ... Ross Foundation to help empower women,battling breast cancer through the charity,s ... has joined the,cause to raise funds for this unique program by ...
... Access to Educational Programming to Promote Stroke Awareness ... Prevention during Stroke Awareness ... and,Comcast have partnered to raise awareness and understanding of the ... through Comcast,s ON DEMAND service. Throughout the month of May,in ...
... a leading healthcare,communications network, announced that Michel Nakache has ... will join Doug Burcin and Donna,Murphy as a Worldwide ... "We,re thrilled to have Michel back at Euro ... a perfect fit for our growing agency,",said Burcin. "Michel,s ...
... new organic 0% fat Greek yogurt flavors to ... satisfy consumers, hungry demands, ... organic yogurt-maker, is expanding the flavor offerings of its,organic, authentically ... yogurts join the Oikos Organic line of,0% fat favorites, Vanilla ...
Cached Medicine News:Health News:AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008 2Health News:AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008 3Health News:Talking up a new role for cell phones in telemedicine 2Health News:Celebrity Mothers and Daughters Including Miley and Trish Cyrus Join Swarovski to Support Breast Cancer Survivors 2Health News:The American Heart Association and Comcast Team Up to Strike Out Stroke 2Health News:The American Heart Association and Comcast Team Up to Strike Out Stroke 3Health News:Michel Nakache Returns to Euro RSCG Life as Worldwide Managing Partner 2Health News:Oikos Organic Greek Yogurt Ventures into the Land of Milk and Honey ... and Blueberry! 2Health News:Oikos Organic Greek Yogurt Ventures into the Land of Milk and Honey ... and Blueberry! 3
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
Medicine Products: